American Diabetes Association Revised Embargo for Rosiglitazone Study

ORLANDO, FL–(Marketwire – June 28, 2010) –  The American Diabetes Association has announced a change in the embargo time of the rosiglitazone study being presented at the 70^th Scientific Session in Orlando, FL. This is part of the Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes (BARI 2D) study, a landmark multicenter trial focusing exclusively on patients with both diabetes and established heart disease. The new embargo time is 4:30 pm (EDT).

The American Diabetes Association thanks the BARI 2D investigators for their collaboration and appreciates their willingness to present this important scientific information to the diabetes community during the 70^th Scientific Sessions. The full scientific disclosure and discussion of these data will be featured at the Late Breaking Clinical Trials session on Tuesday, June 29, 2010 at 8:50 am.

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information, please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>